ADMA ADMA BIOLOGICS, INC.
8-K Current Report
Filed: March 2, 2026
Health Care
Biological Products, (No Diagnostic Substances)ADMA BIOLOGICS, INC. (ADMA) 8-K current report filed with SEC EDGAR on March 2, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items2 items
- Item 7.01: Regulation FD Disclosure
- Item 8.01: Other Events
AI Filing Analysis8-K
Item 7.01 · Regulation FD Disclosure
- • Reg FD disclosure filed March 2, 2026, signed by CEO Adam S. Grossman
- • No substantive operational or financial data disclosed in the filing text itself — material content likely contained in referenced exhibit
Item 8.01 · Other Events
- • $125M ASR with JPMorgan, funded via existing $225M revolving credit facility — part of $500M total buyback program announced May 2025
- • Initial delivery ~6.4M shares (~80% of expected total) on/around March 3, 2026 at reference price of $15.57/share
Other ADMA BIOLOGICS, INC. 8-K Filings
Get deeper insights on ADMA BIOLOGICS, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.